Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Polymer-free stents show comparable PCI results but with increased early thrombosis risk, impacting clinical choices.
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...
Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its planned Phase 3 trial for FLT201, an ...
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Median Technologies now plans to submit its lung cancer diagnostic for regulatory clearance in the US and EU in the coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback